China's Sinovac enters supply deal with Indonesia for COVID-19 vaccine doses

Aug 25 (Reuters) - Sinovac Biotech Ltd SVA.O said on Tuesday it would help Indonesia's state-owned drugmaker Bio Farma produce in the country at least 40 million doses of its potential coronavirus vaccine before March 2021.

The U.S.-listed Chinese drugmaker has signed two agreements with Bio Farma for supply, local production and technology licensing of its vaccine candidate CoronaVac and the Indonesian company is conducting the late-stage study of the candidate.

Sinovac will continue to supply the bulk vaccine until the end of 2021 after March, it said in a statement.

There are no approved vaccine for COVID-19, with drugmakers and research organizations racing to develop a safe and effective vaccine that is seen as crucial to combat the pandemic.

CORRECTED-UPDATE 1-Indonesia books 50 mln coronavirus vaccine doses from Sinovac

FACTBOX- The race for a coronavirus vaccine

FACTBOX-U.S., UK spend billions to take lead in securing coronavirus vaccines

(Reporting by Ankur Banerjee in Bengaluru; Editing by Arun Koyyur)

((ankur.banerjee@thomsonreuters.com;; within U.S. +1 646 223 8780, outside U.S. +91 80 6749 6132; Twitter: @AnkurBanerjee17;))

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

SVA